Very recently we came across several studies in which small differences in design had a major impact on outcomes. A blog is not a good place to dig deeply into the minutiae of study design as the discussion becomes quickly very dry and quite technical. However, readers
Continue reading Is LAIV Dead or Just on LAIV-Support?
Posted in Recent Literature, The News |
Tagged ACIP, Advisory Committee on Immunization Practices, antibiotic blog, AstraZeneca, CDC, effectiveness vs efficacy, Finland, FluMist, Harald Reinhart, IIV, influenza vaccine, injectable influenza vaccine, LAIV, MedImmune, P. aeruginosa. S. aureus, randomized controlled trial, RCT, RSV, Test Negative design, TIV, TND, vaccine effectiveness, vaccine efficacy, VE |
Sometimes – for no obvious reason – there is a flurry of publications from a particular area which has been quiet for a long time. RSV is such an area where new drug development had a hard time getting started.
Continue reading There is Momentum Building for RSV Therapeutics
Posted in Recent Literature, The News, The Viewpoint |
Tagged AIDAC, AL-8176, Alios, Allphase Pharma Consulting, ALS-008176, antibiotic blog, Antiviral Drugs Advisory Committee, AstaZeneca, FDA rejection, Gilead, GS-5806, Harald Reinhart, Johnson & Johnson, mAb, MEDI-524, MedImmune, Motavizumab, Novavax, Numax, Numax efficacy, palivizumab, respiratory syncytial virus, RSV, Synagis |
“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics. Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent
Continue reading Aerosolized Antibiotics & Selling Nebulizers
Posted in QIDP Antibiotics, The News, The Viewpoint |
Tagged AeroVanc, antibiotic blog, Aradigm, Arikayce, aspergillosis, aztreonam, Bayer, bronchiectasis, bronchiolitis, Cardeas, Cayston, ciprofloxacin, cystic fibrosis, DPI, FDA, FEV1, fosfomycin, inhaled antibiotics, Insmed, levofloxacin, Nektar, Novartis, PARI eFlow nebulizer, pentamidine, PodHaler, Pulmosphere, RSV, Sawara, TOBI, tobramycin, vancomycin, Ventolin |
In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2. Since then, it has been very quiet about this compound. Some have suggested that Novartis has stopped development ,
Continue reading Following The Publication Trail of Two RSV Drugs
Posted in The News, The Viewpoint |
Tagged antibiotics blog, AR-60444, Arrow, DeVincenzo, Gilead, GS-5806, NEJM, Novartis, publication bias, respiratory syncytial virus, RSV, RSV-604 |